Chimerix Revenue and Competitors
Estimated Revenue & Valuation
- Chimerix's estimated annual revenue is currently $300M per year.
- Chimerix's estimated revenue per employee is $3,125,000
- Chimerix's total funding is $441.2M.
Employee Data
- Chimerix has 96 Employees.
- Chimerix grew their employee count by -13% last year.
Chimerix's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Technology Officer | Reveal Email/Phone |
2 | VP Strategic Planning and Investor Relations | Reveal Email/Phone |
3 | VP and General Counsel | Reveal Email/Phone |
4 | VP Regulatory Affairs | Reveal Email/Phone |
5 | VP Clinical Pharmacology/Translational Medicine | Reveal Email/Phone |
6 | VP, Biostatistics | Reveal Email/Phone |
7 | VP Clinical Operations | Reveal Email/Phone |
8 | Director, Clinical Quality Assurance | Reveal Email/Phone |
9 | Chief Medical Officer | Reveal Email/Phone |
10 | Associate Director, Lab Management | Reveal Email/Phone |
Chimerix Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.8M | 29 | 4% | N/A | N/A |
#2 | $3.2M | 16 | 0% | N/A | N/A |
#3 | $83.2M | 414 | 7% | N/A | N/A |
#4 | $31M | 154 | 56% | N/A | N/A |
#5 | $66.6M | 265 | 0% | $35M | N/A |
#6 | $10.9M | 54 | 6% | N/A | N/A |
#7 | $6.8M | 34 | -6% | N/A | N/A |
#8 | $165.7M | 216 | 14% | $250.7M | N/A |
#9 | $26.5M | 132 | -11% | $637.8K | N/A |
#10 | $49.4M | 246 | 6% | N/A | N/A |
What Is Chimerix?
Chimerix is developing vitally important new antiviral medicines for the treatment of life-threatening diseases. Led by a world-class team of antiviral experts and pharmaceutical drug developers, we are advancing a rich portfolio of clinical- and early-stage therapeutics to address serious viruses including cytomegalovirus (CMV), smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza.
keywords:Biotechnology, Healthcare
$441.2M
Total Funding
96
Number of Employees
$300M
Revenue (est)
-13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Chimerix News
Comparatively, 6.9% of Chimerix shares are held by insiders. Strong institutional ownership is an indication that large money managers,...
Chimerix (NASDAQ:CMRX) says that recent unusual trading in its stock may be because of statements regarding smallpox antiviral development...
Chimerix logo Analysts forecast that Chimerix, Inc. (NASDAQ:CMRX Get Rating) will report earnings of ($0.35) per share for the current...
Michelle Berrey — the woman who replaced Chimerix CEO Kenneth Moch in 2014 after the company notoriously denied a dying child compassionate use of its experimental treatment — has stepped down for undisclosed reasons, the Durham, North Carolina-based drug developer said ...
Ultimately, the family won. Chimerix initiated a clinical trial of the drug for adenovirus in immunocompromised patients, Hardy got the drug and the treatment worked. Some might point to this case as a fine example of the power of social media. Others, like the Working Group, see it as tragicall ...
Other Companies in Durham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $23.3M | 96 | 7% | N/A |
#2 | $15M | 96 | 25% | N/A |
#3 | $20.4M | 97 | 5% | N/A |
#4 | $20.1M | 98 | 53% | N/A |
#5 | $21.8M | 99 | -1% | N/A |